{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:37:47Z","timestamp":1788536267189,"version":"build-2803163510"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["FDN-143305"],"award-info":[{"award-number":["FDN-143305"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["PJT-153285"],"award-info":[{"award-number":["PJT-153285"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Canadian Cancer Society","award":["705457"],"award-info":[{"award-number":["705457"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Metastatic breast cancer is a leading cause of cancer death in woman. Current treatment options are often associated with adverse side effects and poor outcomes, demonstrating the need for effective new treatments. Immunotherapies can provide durable outcomes in many cancers; however, limited success has been achieved in metastatic triple negative breast cancer. We tested whether combining different immunotherapies can target metastatic triple negative breast cancer in pre-clinical models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using primary and metastatic 4T1 triple negative mammary carcinoma models, we examined the therapeutic effects of oncolytic vesicular stomatitis virus (VSV\u0394M51) engineered to express reovirus-derived fusion associated small transmembrane proteins p14 (VSV-p14) or p15 (VSV-p15). These viruses were delivered alone or in combination with natural killer T (NKT) cell activation therapy mediated by adoptive transfer of \u03b1-galactosylceramide-loaded dendritic cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Treatment of primary 4T1 tumors with VSV-p14 or VSV-p15 alone increased immunogenic tumor cell death, attenuated tumor growth, and enhanced immune cell infiltration and activation compared to control oncolytic virus (VSV-GFP) treatments and untreated mice. When combined with NKT cell activation therapy, oncolytic VSV-p14 and VSV-p15 reduced metastatic lung burden to undetectable levels in all mice and generated immune memory as evidenced by enhanced in vitro recall responses (tumor killing and cytokine production) and impaired tumor growth upon rechallenge.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Combining NKT cell immunotherapy with enhanced oncolytic virotherapy increased anti-tumor immune targeting of lung metastasis and presents a promising treatment strategy for metastatic breast cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13058-024-01818-5","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T08:02:59Z","timestamp":1715760179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Adam","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichole","family":"McMullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Gebremeskel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"De Antueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"1818_CR1","doi-asserted-by":"publisher","unstructured":"Siegel RL, Miller KD, Jemal A, Cancer statistics, 2019. CA Cancer J Clin 2019;69:7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","DOI":"10.3322\/caac.21551"},{"key":"1818_CR2","first-page":"106","volume":"12","author":"HA Wahba","year":"2015","unstructured":"Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12:106\u201316.","journal-title":"Cancer Biol Med"},{"key":"1818_CR3","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.3816\/CBC.2009.s.008","volume":"9","author":"CK Anders","year":"2009","unstructured":"Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009;9:S73\u201381. https:\/\/doi.org\/10.3816\/CBC.2009.s.008.","journal-title":"Clin Breast Cancer"},{"key":"1818_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nrc.2016.25","volume":"16","author":"PS Steeg","year":"2016","unstructured":"Steeg PS. Targeting metastasis. Nat Rev Cancer. 2016;16:201\u201318. https:\/\/doi.org\/10.1038\/nrc.2016.25.","journal-title":"Nat Rev Cancer"},{"key":"1818_CR5","doi-asserted-by":"crossref","unstructured":"Wysocki PJ, Korski K, Lamperska K, Zaluski J, Mackiewicz A. Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations. Med Sci Monit. 2008;14:SC7\u201310. http:\/\/www.medscimonit.com\/abstract\/index\/idArt\/863649","DOI":"10.1200\/jco.2008.26.15_suppl.1079"},{"key":"1818_CR6","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.3892\/ol.2017.7473","volume":"15","author":"B Hryciuk","year":"2018","unstructured":"Hryciuk B, Szymanowski B, Romanowska A, Salt E, Was\u0105g B, Grala B, et al. Severe acute toxicity following gemcitabine administration: a report of four cases with cytidine deaminase polymorphisms evaluation. Oncol Lett. 2018;15:1912\u20136. https:\/\/doi.org\/10.3892\/ol.2017.7473.","journal-title":"Oncol Lett"},{"key":"1818_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000086183","volume":"14","author":"YA Luqmani","year":"2005","unstructured":"Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract. 2005;14:35\u201348. https:\/\/doi.org\/10.1159\/000086183.","journal-title":"Med Princ Pract"},{"key":"1818_CR8","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.it.2019.09.008","volume":"40","author":"S-I Fujii","year":"2019","unstructured":"Fujii S-I, Shimizu K. Immune networks and therapeutic targeting of iNKT cells in cancer. Trends Immunol. 2019;40:984\u201397. https:\/\/doi.org\/10.1016\/j.it.2019.09.008.","journal-title":"Trends Immunol"},{"key":"1818_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1158\/2326-6066.CIR-15-0062","volume":"3","author":"RM McEwen-Smith","year":"2015","unstructured":"McEwen-Smith RM, Salio M, Cerundolo V. The regulatory role of invariant NKT cells in tumor immunity. Cancer Immunol Res. 2015;3:425\u201335. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0062.","journal-title":"Cancer Immunol Res"},{"key":"1818_CR10","doi-asserted-by":"publisher","first-page":"5174","DOI":"10.3390\/cancers13205174","volume":"13","author":"A Nelson","year":"2021","unstructured":"Nelson A, Lukacs JD, Johnston B. The current landscape of NKT cell immunotherapy and the hills ahead. Cancers (Basel). 2021;13:5174. https:\/\/doi.org\/10.3390\/cancers13205174.","journal-title":"Cancers (Basel)"},{"key":"1818_CR11","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1084\/jem.191.11.1895","volume":"191","author":"K Benlagha","year":"2000","unstructured":"Benlagha K, Weiss A, Beavis A, Teyton L, Bendelac A. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J Exp Med. 2000;191:1895\u2013903. https:\/\/doi.org\/10.1084\/jem.191.11.1895.","journal-title":"J Exp Med"},{"key":"1818_CR12","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/ni827","volume":"3","author":"S Fujii","year":"2002","unstructured":"Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-\u03b3-producing NKT response induced with \u03b1-galactosylceramide-loaded DCs. Nat Immunol. 2002;3:867\u201374. https:\/\/doi.org\/10.1038\/ni827","journal-title":"Nat Immunol"},{"key":"1818_CR13","doi-asserted-by":"publisher","first-page":"e995562","DOI":"10.1080\/2162402X.2014.995562","volume":"4","author":"S Gebremeskel","year":"2015","unstructured":"Gebremeskel S, Clattenburg DR, Slauenwhite D, Lobert L, Johnston B. Natural killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice. Oncoimmunology. 2015;4:e995562. https:\/\/doi.org\/10.1080\/2162402X.2014.995562.","journal-title":"Oncoimmunology"},{"key":"1818_CR14","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.4049\/jimmunol.163.5.2387","volume":"163","author":"I Toura","year":"1999","unstructured":"Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with \u03b1-galactosylceramide. J Immunol. 1999;163:2387\u201391.","journal-title":"J Immunol"},{"key":"1818_CR15","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.4049\/jimmunol.167.6.3114","volume":"167","author":"LS Metelitsa","year":"2001","unstructured":"Metelitsa LS, Naidenko OV, Kant A, Wu H-W, Loza MJ, Perussia B, et al. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol. 2001;167:3114\u201322. https:\/\/doi.org\/10.4049\/jimmunol.167.6.3114.","journal-title":"J Immunol"},{"key":"1818_CR16","doi-asserted-by":"publisher","first-page":"5807","DOI":"10.4049\/jimmunol.0803520","volume":"183","author":"R Cullen","year":"2009","unstructured":"Cullen R, Germanov E, Shimaoka T, Johnston B. Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation. J Immunol. 2009;183:5807\u201315. https:\/\/doi.org\/10.4049\/jimmunol.0803520.","journal-title":"J Immunol"},{"key":"1818_CR17","doi-asserted-by":"publisher","first-page":"11287","DOI":"10.1073\/pnas.0801631105","volume":"105","author":"JM Coquet","year":"2008","unstructured":"Coquet JM, Chakravarti S, Kyparissoudis K, McNab FW, Pitt LA, McKenzie BS, et al. Diverse cytokine production by NKT cell subsets and identification of an IL-17\u2013producing CD4\u2009\u2013\u2009NK1.1\u2009\u2013\u2009NKT cell population. Proc Natl Acad Sci USA. 2008;105:11287\u201392. https:\/\/doi.org\/10.1073\/pnas.0801631105","journal-title":"Proc Natl Acad Sci"},{"key":"1818_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.clim.2011.01.009","volume":"140","author":"S Motohashi","year":"2011","unstructured":"Motohashi S, Okamoto Y, Yoshino I, Nakayama T. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clin Immunol. 2011;140:167\u201376. https:\/\/doi.org\/10.1016\/j.clim.2011.01.009.","journal-title":"Clin Immunol"},{"key":"1818_CR19","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1084\/jem.20031462","volume":"199","author":"LS Metelitsa","year":"2004","unstructured":"Metelitsa LS, Wu H-W, Wang H, Yang Y, Warsi Z, Asgharzadeh S, et al. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med. 2004;199:1213\u201321. https:\/\/doi.org\/10.1084\/jem.20031462.","journal-title":"J Exp Med"},{"key":"1818_CR20","doi-asserted-by":"publisher","first-page":"e0156497","DOI":"10.1371\/journal.pone.0156497","volume":"11","author":"S Lundgren","year":"2016","unstructured":"Lundgren S, Warfvinge CF, Elebro J, Heby M, Nodin B, Krzyzanowska A, et al. The prognostic impact of NK\/NKT cell density in periampullary adenocarcinoma differs by morphological type and adjuvant treatment. PLoS ONE. 2016;11:e0156497. https:\/\/doi.org\/10.1371\/journal.pone.0156497","journal-title":"PLoS ONE"},{"key":"1818_CR21","doi-asserted-by":"publisher","first-page":"7322","DOI":"10.1158\/1078-0432.CCR-05-0877","volume":"11","author":"T Tachibana","year":"2005","unstructured":"Tachibana T. Increased intratumor V\u03b124-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res. 2005;11:7322\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-0877","journal-title":"Clin Cancer Res"},{"key":"1818_CR22","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/2326-6066.CIR-17-0229","volume":"5","author":"S Gebremeskel","year":"2017","unstructured":"Gebremeskel S, Lobert L, Tanner K, Walker B, Oliphant T, Clarke LE, et al. Natural killer T-cell immunotherapy in combination with chemotherapy-induced immunogenic cell death targets metastatic breast cancer. Cancer Immunol Res. 2017;5:1086\u201397. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0229.","journal-title":"Cancer Immunol Res"},{"key":"1818_CR23","doi-asserted-by":"publisher","first-page":"e002096","DOI":"10.1136\/jitc-2020-002096","volume":"9","author":"S Gebremeskel","year":"2021","unstructured":"Gebremeskel S, Nelson A, Walker B, Oliphant T, Lobert L, Mahoney D, et al. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis. J Immunother Cancer. 2021;9:e002096. https:\/\/doi.org\/10.1136\/jitc-2020-002096.","journal-title":"J Immunother Cancer"},{"key":"1818_CR24","doi-asserted-by":"publisher","first-page":"13543","DOI":"10.1128\/JVI.02240-13","volume":"87","author":"A Ammayappan","year":"2013","unstructured":"Ammayappan A, Peng K-W, Russell SJ. Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands. J Virol. 2013;87:13543\u201355. https:\/\/doi.org\/10.1128\/JVI.02240-13.","journal-title":"J Virol"},{"key":"1818_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","volume":"4","author":"DF Stojdl","year":"2003","unstructured":"Stojdl DF, Lichty BD, TenOever BR, Paterson JM, Power AT, Knowles S, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003;4:263\u201375. https:\/\/doi.org\/10.1016\/S1535-6108(03)00241-1.","journal-title":"Cancer Cell"},{"key":"1818_CR26","doi-asserted-by":"publisher","first-page":"7720","DOI":"10.1038\/sj.onc.1209041","volume":"24","author":"M Shmulevitz","year":"2005","unstructured":"Shmulevitz M, Marcato P, Lee PWK. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene. 2005;24:7720\u20138. https:\/\/doi.org\/10.1038\/sj.onc.1209041.","journal-title":"Oncogene"},{"key":"1818_CR27","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc3770","volume":"14","author":"BD Lichty","year":"2014","unstructured":"Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14:559\u201367. https:\/\/doi.org\/10.1038\/nrc3770.","journal-title":"Nat Rev Cancer"},{"key":"1818_CR28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","volume":"17","author":"A Lemos de Matos","year":"2020","unstructured":"Lemos de Matos A, Franco LS, McFadden G. Oncolytic viruses and the immune system: the dynamic duo. Mol Ther Methods Clin Dev. 2020;17:349\u201358. https:\/\/doi.org\/10.1016\/j.omtm.2020.01.001.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1818_CR29","doi-asserted-by":"publisher","first-page":"e003923","DOI":"10.1136\/jitc-2021-003923","volume":"10","author":"A Nelson","year":"2022","unstructured":"Nelson A, Gebremeskel S, Lichty BD, Johnston B. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression. J Immunother Cancer. 2022;10:e003923. https:\/\/doi.org\/10.1136\/jitc-2021-003923.","journal-title":"J Immunother Cancer"},{"key":"1818_CR30","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.1128\/jvi.77.8.4646-4657.2003","volume":"77","author":"M Ahmed","year":"2003","unstructured":"Ahmed M, McKenzie MO, Puckett S, Hojnacki M, Poliquin L, Lyles DS. Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J Virol. 2003;77:4646\u201357. https:\/\/doi.org\/10.1128\/jvi.77.8.4646-4657.2003.","journal-title":"J Virol"},{"key":"1818_CR31","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1182\/blood-2015-06-652503","volume":"127","author":"W Shen","year":"2016","unstructured":"Shen W, Patnaik MM, Ruiz A, Russell SJ, Peng K-W. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood. 2016;127:1449\u201358. https:\/\/doi.org\/10.1182\/blood-2015-06-652503.","journal-title":"Blood"},{"key":"1818_CR32","doi-asserted-by":"publisher","unstructured":"VanSeggelen H, Tantalo DGM, Afsahi A, Hammill JA, Bramson JL. Chimeric antigen receptor-engineered T cells as oncolytic virus carriers. Mol Ther - Oncolytics. 2015;2. https:\/\/doi.org\/10.1038\/mto.2015.14.","DOI":"10.1038\/mto.2015.14"},{"key":"1818_CR33","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1073\/pnas.92.10.4477","volume":"92","author":"ND Lawson","year":"1995","unstructured":"Lawson ND, Stillman EA, Whitt MA, Rose JK. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A. 1995;92:4477\u201381. https:\/\/doi.org\/10.1073\/pnas.92.10.4477.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1818_CR34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.omto.2017.08.001","volume":"6","author":"F Le Boeuf","year":"2017","unstructured":"Le Boeuf F, Gebremeskel S, McMullen N, He H, Greenshields AL, Hoskin DW, et al. Reovirus FAST protein enhances vesicular stomatitis virus oncolytic virotherapy in primary and metastatic tumor models. Mol Ther Oncolytics. 2017;6:80\u20139. https:\/\/doi.org\/10.1016\/j.omto.2017.08.001.","journal-title":"Mol Ther Oncolytics"},{"key":"1818_CR35","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.tim.2014.08.005","volume":"22","author":"M Ciechonska","year":"2014","unstructured":"Ciechonska M, Duncan R, Reovirus. FAST proteins: virus-encoded cellular fusogens. Trends Microbiol. 2014;22:715\u201324. https:\/\/doi.org\/10.1016\/j.tim.2014.08.005.","journal-title":"Trends Microbiol"},{"key":"1818_CR36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1146\/annurev-virology-092818-015523","volume":"6","author":"R Duncan","year":"2019","unstructured":"Duncan R. Fusogenic reoviruses and their fusion-associated small transmembrane (FAST) proteins. Annu Rev Virol. 2019;6:341\u201363. https:\/\/doi.org\/10.1146\/annurev-virology-092818-015523.","journal-title":"Annu Rev Virol"},{"key":"1818_CR37","doi-asserted-by":"publisher","first-page":"8090","DOI":"10.1128\/JVI.79.13.8090-8100.2005","volume":"79","author":"J Salsman","year":"2005","unstructured":"Salsman J, Top D, Boutilier J, Duncan R. Extensive syncytium formation mediated by the reovirus FAST proteins triggers apoptosis-induced membrane instability. J Virol. 2005;79:8090\u2013100. https:\/\/doi.org\/10.1128\/JVI.79.13.8090-8100.2005.","journal-title":"J Virol"},{"key":"1818_CR38","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1038\/sj.emboj.7600767","volume":"24","author":"D Top","year":"2005","unstructured":"Top D, de Antueno R, Salsman J, Corcoran J, Mader J, Hoskin D, et al. Liposome reconstitution of a minimal protein-mediated membrane fusion machine. EMBO J. 2005;24:2980\u20138. https:\/\/doi.org\/10.1038\/sj.emboj.7600767.","journal-title":"EMBO J"},{"key":"1818_CR39","doi-asserted-by":"publisher","first-page":"e1000016","DOI":"10.1371\/journal.ppat.1000016","volume":"4","author":"J Salsman","year":"2008","unstructured":"Salsman J, Top D, Barry C, Duncan R. A virus-encoded cell\u2013cell fusion machine dependent on surrogate adhesins. PLOS Pathog. 2008;4:e1000016. https:\/\/doi.org\/10.1371\/journal.ppat.1000016","journal-title":"PLOS Pathog"},{"key":"1818_CR40","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1128\/JVI.00171-09","volume":"83","author":"T Racine","year":"2009","unstructured":"Racine T, Hurst T, Barry C, Shou J, Kibenge F, Duncan R. Aquareovirus effects syncytiogenesis by using a novel member of the FAST protein family translated from a noncanonical translation start site. J Virol. 2009;83:5951\u20135. https:\/\/doi.org\/10.1128\/JVI.00171-09.","journal-title":"J Virol"},{"key":"1818_CR41","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/mt.2010.44","volume":"18","author":"F Le Boeuf","year":"2010","unstructured":"Le Boeuf F, Diallo J-S, McCart JA, Thorne S, Falls T, Stanford M, et al. Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther. 2010;18:888\u201395. https:\/\/doi.org\/10.1038\/mt.2010.44.","journal-title":"Mol Ther"},{"key":"1818_CR42","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/1087057107306839","volume":"12","author":"J Friedrich","year":"2007","unstructured":"Friedrich J, Eder W, Castaneda J, Doss M, Huber E, Ebner R, et al. A reliable tool to determine cell viability in complex 3-D culture: the acid phosphatase assay. J Biomol Screen. 2007;12:925\u201337. https:\/\/doi.org\/10.1177\/1087057107306839.","journal-title":"J Biomol Screen"},{"key":"1818_CR43","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ymeth.2015.09.004","volume":"90","author":"JL Perry","year":"2015","unstructured":"Perry JL, Ramachandran NK, Utama B, Hyser JM. Use of genetically-encoded calcium indicators for live cell calcium imaging and localization in virus-infected cells. Methods. 2015;90:28\u201338. https:\/\/doi.org\/10.1016\/j.ymeth.2015.09.004.","journal-title":"Methods"},{"key":"1818_CR44","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41592-020-01018-x","volume":"18","author":"C Stringer","year":"2021","unstructured":"Stringer C, Wang T, Michaelos M, Pachitariu M. Cellpose: a generalist algorithm for cellular segmentation. Nat Methods. 2021;18:100\u20136. https:\/\/doi.org\/10.1038\/s41592-020-01018-x.","journal-title":"Nat Methods"},{"key":"1818_CR45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1101\/pdb.top066050","volume":"2013","author":"MD Bootman","year":"2013","unstructured":"Bootman MD, Rietdorf K, Collins T, Walker S, Sanderson M. Ca2+-sensitive fluorescent dyes and intracellular Ca2\u2009+\u2009imaging. Cold Spring Harb Protoc. 2013;2013:83\u2013100. https:\/\/doi.org\/10.1101\/pdb.top066050","journal-title":"Cold Spring Harb Protoc"},{"key":"1818_CR46","doi-asserted-by":"publisher","unstructured":"Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol. 2000;39:20.2.16. https:\/\/doi.org\/10.1002\/0471142735.im2002s39","DOI":"10.1002\/0471142735.im2002s39"},{"key":"1818_CR47","doi-asserted-by":"publisher","first-page":"e1462431","DOI":"10.1080\/2162402X.2018.1462431","volume":"7","author":"DP Enot","year":"2018","unstructured":"Enot DP, Vacchelli E, Jacquelot N, Zitvogel L, Kroemer G, TumGrowth: an open-access web tool for the statistical analysis of tumor growth curves. Oncoimmunology. 2018;7:e1462431. https:\/\/doi.org\/10.1080\/2162402X.2018.1462431","journal-title":"Oncoimmunology"},{"key":"1818_CR48","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/cgt.2010.46","volume":"17","author":"M Ahmed","year":"2010","unstructured":"Ahmed M, Puckett S, Lyles DS. Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus. Cancer Gene Ther. 2010;17:883\u201392. https:\/\/doi.org\/10.1038\/cgt.2010.46.","journal-title":"Cancer Gene Ther"},{"key":"1818_CR49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97\u2013111. https:\/\/doi.org\/10.1038\/nri.2016.107.","journal-title":"Nat Rev Immunol"},{"key":"1818_CR50","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/emboj.2009.1","volume":"28","author":"T Panaretakis","year":"2009","unstructured":"Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund A-C, Chapman DC, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 2009;28:578\u201390. https:\/\/doi.org\/10.1038\/emboj.2009.1.","journal-title":"EMBO J"},{"key":"1818_CR51","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cytogfr.2013.05.001","volume":"24","author":"O Kepp","year":"2013","unstructured":"Kepp O, Menger L, Vacchelli E, Locher C, Adjemian S, Yamazaki T, et al. Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor Rev. 2013;24:311\u20138. https:\/\/doi.org\/10.1016\/j.cytogfr.2013.05.001.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1818_CR52","doi-asserted-by":"publisher","first-page":"6137","DOI":"10.1128\/JVI.00121-14","volume":"88","author":"M Ciechonska","year":"2014","unstructured":"Ciechonska M, Key T, Duncan R. Efficient reovirus- and measles virus-mediated pore expansion during syncytium formation is dependent on annexin A1 and intracellular calcium. J Virol. 2014;88:6137\u201347. https:\/\/doi.org\/10.1128\/JVI.00121-14.","journal-title":"J Virol"},{"key":"1818_CR53","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1126\/science.abc3621","volume":"370","author":"AL Chang-Graham","year":"2020","unstructured":"Chang-Graham AL, Perry JL, Engevik MA, Engevik KA, Scribano FJ, Gebert JT, et al. Rotavirus induces intercellular calcium waves through ADP signaling. Science. 2020;370:909\u201310. https:\/\/doi.org\/10.1126\/science.abc3621.","journal-title":"Science"},{"key":"1818_CR54","doi-asserted-by":"publisher","first-page":"54-61","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini J-L, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54\u201361. https:\/\/doi.org\/10.1038\/nm1523","journal-title":"Nat Med"},{"key":"1818_CR55","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/sj.cdd.4402275","volume":"15","author":"R Tufi","year":"2008","unstructured":"Tufi R, Panaretakis T, Bianchi K, Criollo A, Fazi B, Di Sano F, et al. Reduction of endoplasmic reticulum Ca2\u2009+\u2009levels favors plasma membrane surface exposure of calreticulin. Cell Death Differ. 2008;15:274\u201382. https:\/\/doi.org\/10.1038\/sj.cdd.4402275","journal-title":"Cell Death Differ"},{"key":"1818_CR56","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4\u2013dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050\u20139. https:\/\/doi.org\/10.1038\/nm1622.","journal-title":"Nat Med"},{"key":"1818_CR57","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm.3708","volume":"20","author":"A Sistigu","year":"2014","unstructured":"Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, et al. Cancer cell\u2013autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20:1301\u20139. https:\/\/doi.org\/10.1038\/nm.3708.","journal-title":"Nat Med"},{"key":"1818_CR58","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41417-018-0074-6","volume":"26","author":"MR Patel","year":"2019","unstructured":"Patel MR, Dash A, Jacobson BA, Ji Y, Baumann D, Ismail K, et al. JAK\/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models. Cancer Gene Ther. 2019;26:411\u20138. https:\/\/doi.org\/10.1038\/s41417-018-0074-6.","journal-title":"Cancer Gene Ther"},{"key":"1818_CR59","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1128\/jvi.01921-08","volume":"83","author":"C Brown","year":"2009","unstructured":"Brown C, Stephenson KB, Hanson S, Kucharczyk M, Duncan R, Bell JC, et al. The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. J Virol. 2009;83:552\u201361. https:\/\/doi.org\/10.1128\/jvi.01921-08.","journal-title":"J Virol"},{"key":"1818_CR60","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.omto.2019.09.006","volume":"15","author":"C Burton","year":"2019","unstructured":"Burton C, Bartee E. Syncytia formation in oncolytic virotherapy. Mol Ther - Oncolytics. 2019;15:131\u20139. https:\/\/doi.org\/10.1016\/j.omto.2019.09.006.","journal-title":"Mol Ther - Oncolytics"},{"key":"1818_CR61","first-page":"6566","volume":"62","author":"AR Bateman","year":"2002","unstructured":"Bateman AR, Harrington KJ, Kottke T, Ahmed A, Melcher AA, Gough MJ, et al. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res. 2002;62:6566\u201378.","journal-title":"Cancer Res"},{"key":"1818_CR62","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3892\/ijmm.20.5.673","volume":"20","author":"D Hoffmann","year":"2007","unstructured":"Hoffmann D, Bayer W, Wildner O. Therapeutic immune response induced by intratumoral expression of the fusogenic membrane protein of vesicular stomatitis virus and cytokines encoded by adenoviral vectors. Int J Mol Med. 2007;20:673\u201381. https:\/\/doi.org\/10.3892\/ijmm.20.5.673.","journal-title":"Int J Mol Med"},{"key":"1818_CR63","doi-asserted-by":"publisher","unstructured":"Yang Y, Gaspard G, McMullen N, Duncan R. Polycistronic genome segment evolution and gain and loss of FAST protein function during fusogenic orthoreovirus speciation. Viruses 2020;12:702 https:\/\/doi.org\/10.3390\/v12070702","DOI":"10.3390\/v12070702"},{"key":"1818_CR64","doi-asserted-by":"publisher","first-page":"4707","DOI":"10.1128\/jvi.02223-10","volume":"85","author":"EK Clancy","year":"2011","unstructured":"Clancy EK, Duncan R. Helix-destabilizing, \u03b2-branched, and polar residues in the baboon reovirus p15 transmembrane domain influence the modularity of FAST proteins. J Virol. 2011;85:4707\u201319. https:\/\/doi.org\/10.1128\/jvi.02223-10.","journal-title":"J Virol"},{"key":"1818_CR65","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1128\/JVI.01869-08","volume":"83","author":"EK Clancy","year":"2009","unstructured":"Clancy EK, Duncan R. Reovirus FAST protein transmembrane domains function in a modular, primary sequence-independent manner to mediate cell-cell membrane fusion. J Virol. 2009;83:2941\u201350. https:\/\/doi.org\/10.1128\/JVI.01869-08.","journal-title":"J Virol"},{"key":"1818_CR66","doi-asserted-by":"publisher","first-page":"51386","DOI":"10.1074\/jbc.M406990200","volume":"279","author":"JA Corcoran","year":"2004","unstructured":"Corcoran JA, Syvitski R, Top D, Epand RM, Epand RF, Jakeman D, et al. Myristoylation, a protruding loop, and structural plasticity are essential features of a nonenveloped virus fusion peptide motif. J Biol Chem. 2004;279:51386\u201394. https:\/\/doi.org\/10.1074\/jbc.M406990200.","journal-title":"J Biol Chem"},{"key":"1818_CR67","doi-asserted-by":"publisher","first-page":"6216","DOI":"10.1128\/jvi.79.10.6216-6226.2005","volume":"79","author":"D Sandra","year":"2005","unstructured":"Sandra D, CJ A, CE K, Jayme S, Roy D. Unusual topological arrangement of structural motifs in the baboon reovirus fusion-associated small transmembrane protein. J Virol. 2005;79:6216\u201326. https:\/\/doi.org\/10.1128\/jvi.79.10.6216-6226.2005.","journal-title":"J Virol"},{"key":"1818_CR68","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/gt.2009.161","volume":"17","author":"F Galivo","year":"2010","unstructured":"Galivo F, Diaz RM, Wongthida P, Thompson J, Kottke T, Barber G, et al. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther. 2010;17:158\u201370. https:\/\/doi.org\/10.1038\/gt.2009.161.","journal-title":"Gene Ther"},{"key":"1818_CR69","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1158\/1078-0432.CCR-09-0334","volume":"15","author":"RJ Prestwich","year":"2009","unstructured":"Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, et al. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res. 2009;15:4374\u201381. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0334.","journal-title":"Clin Cancer Res"},{"key":"1818_CR70","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/mt.2014.60","volume":"22","author":"J Zhang","year":"2014","unstructured":"Zhang J, Tai L-H, Ilkow CS, Alkayyal AA, Ananth AA, de Souza CT, et al. Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease. Mol Ther. 2014;22:1320\u201332. https:\/\/doi.org\/10.1038\/mt.2014.60.","journal-title":"Mol Ther"},{"key":"1818_CR71","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","volume":"10","author":"P Bonaventura","year":"2019","unstructured":"Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019;10:168. https:\/\/doi.org\/10.3389\/fimmu.2019.00168.","journal-title":"Front Immunol"},{"key":"1818_CR72","doi-asserted-by":"publisher","unstructured":"Wang Q, Yuan X, Chen Y, Zheng Q, Xu L, Wu Y. Endoplasmic reticulum stress mediated MDRV p10.8 protein-induced cell cycle arrest and apoptosis through the PERK\/eIF2\u03b1 pathway. Front Microbiol 2018;9:1327. https:\/\/doi.org\/10.3389\/fmicb.2018.01327","DOI":"10.3389\/fmicb.2018.01327"},{"key":"1818_CR73","first-page":"6396","volume":"60","author":"H Higuchi","year":"2000","unstructured":"Higuchi H, Bronk SF, Bateman A, Harrington K, Vile RG, Gores GJ. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy. Cancer Res. 2000;60:6396\u2013402.","journal-title":"Cancer Res"},{"key":"1818_CR74","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1189\/jlb.0306171","volume":"81","author":"IE Dumitriu","year":"2007","unstructured":"Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere-Querini P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol. 2007;81:84\u201391. https:\/\/doi.org\/10.1189\/jlb.0306171.","journal-title":"J Leukoc Biol"},{"key":"1818_CR75","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.4049\/jimmunol.171.6.2960","volume":"171","author":"B Johnston","year":"2003","unstructured":"Johnston B, Kim CH, Soler D, Emoto M, Butcher EC. Differential chemokine responses and homing patterns of murine TCR\u03b1\u03b2 NKT cell subsets. J Immunol. 2003;171:2960\u20139. https:\/\/doi.org\/10.4049\/jimmunol.171.6.2960","journal-title":"J Immunol"},{"key":"1818_CR76","doi-asserted-by":"publisher","first-page":"961","DOI":"10.4049\/jimmunol.1303029","volume":"193","author":"E Macho-Fernandez","year":"2014","unstructured":"Macho-Fernandez E, Cruz LJ, Ghinnagow R, Fontaine J, Bialecki E, Frisch B, et al. Targeted delivery of \u03b1-galactosylceramide to CD8\u03b1\u2009+\u2009dendritic cells optimizes type I NKT cell\u2013based antitumor responses. J Immunol. 2014;193:961\u20139. https:\/\/doi.org\/10.4049\/jimmunol.1303029","journal-title":"J Immunol"},{"key":"1818_CR77","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045.","journal-title":"Clin Cancer Res"},{"key":"1818_CR78","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30:658\u201370. https:\/\/doi.org\/10.1038\/nbt.2287.","journal-title":"Nat Biotechnol"},{"key":"1818_CR79","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3389\/fimmu.2017.01178","volume":"8","author":"S Nair","year":"2017","unstructured":"Nair S, Dhodapkar MV. Natural killer T cells in cancer immunotherapy. Front Immunol. 2017;8:1178. https:\/\/doi.org\/10.3389\/fimmu.2017.01178.","journal-title":"Front Immunol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-024-01818-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-024-01818-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-024-01818-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T08:06:24Z","timestamp":1715760384000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-024-01818-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1818"],"URL":"https:\/\/doi.org\/10.1186\/s13058-024-01818-5","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]},"assertion":[{"value":"6 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental procedures were approved by the University Committee on Laboratory Animals following the guidelines of the Canadian Council on Animal Care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R.D. is a minority shareholder and board member of Entos Pharmaceuticals. The authors have no additional financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}